IL139528A - Platinum bracelets, processes for their preparation and pharmaceutical preparations containing them - Google Patents
Platinum bracelets, processes for their preparation and pharmaceutical preparations containing themInfo
- Publication number
- IL139528A IL139528A IL13952899A IL13952899A IL139528A IL 139528 A IL139528 A IL 139528A IL 13952899 A IL13952899 A IL 13952899A IL 13952899 A IL13952899 A IL 13952899A IL 139528 A IL139528 A IL 139528A
- Authority
- IL
- Israel
- Prior art keywords
- carbon atoms
- platinum complex
- general formula
- complex
- optionally substituted
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 150000003057 platinum Chemical class 0.000 title description 11
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 53
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 28
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 17
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims abstract description 11
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims abstract description 11
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 9
- 229960004853 betadex Drugs 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 5
- 230000003647 oxidation Effects 0.000 claims abstract description 5
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 5
- 125000005843 halogen group Chemical group 0.000 claims abstract description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000000771 oncological effect Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- -1 alkali metal salt Chemical class 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 239000003495 polar organic solvent Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- SDIXRDNYIMOKSG-UHFFFAOYSA-L disodium methyl arsenate Chemical compound [Na+].[Na+].C[As]([O-])([O-])=O SDIXRDNYIMOKSG-UHFFFAOYSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012982 x-ray structure analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ19981627A CZ288406B6 (en) | 1998-05-27 | 1998-05-27 | Platinum complex of oxidation number II, process for preparing such complex, the complex functioning as medicament and pharmaceutical composition in which the complex is comprised |
| PCT/CZ1999/000014 WO1999061450A1 (en) | 1998-05-27 | 1999-05-24 | Platinum complex, its preparation and therapeutic application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL139528A0 IL139528A0 (en) | 2001-11-25 |
| IL139528A true IL139528A (en) | 2004-06-20 |
Family
ID=5463561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13952899A IL139528A (en) | 1998-05-27 | 1999-05-24 | Platinum bracelets, processes for their preparation and pharmaceutical preparations containing them |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6350737B1 (ja) |
| EP (1) | EP1082329B1 (ja) |
| JP (1) | JP3647748B2 (ja) |
| CN (1) | CN1124278C (ja) |
| AU (1) | AU741381B2 (ja) |
| BG (1) | BG64598B1 (ja) |
| BR (1) | BR9910668A (ja) |
| CA (1) | CA2331464C (ja) |
| CZ (1) | CZ288406B6 (ja) |
| DE (1) | DE69905714T2 (ja) |
| ES (1) | ES2194457T3 (ja) |
| HR (1) | HRP20000792B1 (ja) |
| HU (1) | HU228940B1 (ja) |
| IL (1) | IL139528A (ja) |
| NO (1) | NO328940B1 (ja) |
| PL (1) | PL191131B1 (ja) |
| RS (1) | RS49739B (ja) |
| RU (1) | RU2203901C2 (ja) |
| SK (1) | SK284398B6 (ja) |
| UA (1) | UA56314C2 (ja) |
| WO (1) | WO1999061450A1 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005102312A1 (en) * | 2004-04-27 | 2005-11-03 | Mayne Pharma Limited | Concentrated oxaliplatin solutions |
| EP2298291A3 (en) | 2004-06-18 | 2011-08-03 | Agennix USA Inc. | Kinase inhibitors for treating cancers |
| AU2005275205A1 (en) * | 2004-07-14 | 2006-02-23 | Gpc Biotech Ag | Variable-dose packaging system |
| CZ296459B6 (cs) * | 2004-09-14 | 2006-03-15 | Pliva-Lachema A. S. | Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo |
| CZ300120B6 (cs) * | 2006-06-20 | 2009-02-11 | Pliva - Lachema A. S. | Farmaceutická kompozice pro injekcní podání |
| WO2011029639A2 (en) | 2009-09-08 | 2011-03-17 | Medexis S.A. | Compounds and methods for treating neoplasia |
| HRP20211709T8 (hr) * | 2014-04-04 | 2022-03-04 | Taiho Pharmaceutical Co., Ltd. | Antitumorski lijek koji sadrži antitumorski kompleks platine, i pojačivač antitumorskog efekta |
| CN104922688A (zh) * | 2015-02-10 | 2015-09-23 | 昆明贵研药业有限公司 | 奥沙利铂的环糊精复合物及制备方法 |
| CN104984356A (zh) * | 2015-05-14 | 2015-10-21 | 昆明贵研药业有限公司 | 赛特铂的环糊精复合物及制备方法 |
| RU2613513C2 (ru) * | 2015-07-17 | 2017-03-16 | Федеральное государственное бюджетное учреждение науки Институт проблем химической физики Российской академии наук (ИПХФ РАН) | Способ получения комплексов платины (IV) с аминонитроксильными радикалами |
| RU2726826C2 (ru) * | 2016-12-27 | 2020-07-15 | Общество с ограниченной ответственностью "Плат-АН" (ООО "Плат-АН") | Композиция на основе аминонитроксильного комплекса платины и доксорубицина и способ лечения опухолей |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA805101B (en) * | 1979-08-23 | 1981-08-26 | Johnson Matthey Co Ltd | Compositions containing platinium |
| ES2032430T3 (es) * | 1986-12-18 | 1993-02-16 | Shionogi Seiyaku Kabushiki Kaisha Trading Under The Name Of Shionogi & Co. Ltd. | Un procedimiento para la preparacion de nuevos complejos amina-platino ammina-aliciclicos que muestran potentes actividades antitumorales. |
| US5225207A (en) * | 1989-03-17 | 1993-07-06 | Laboratoire Roger Bellon | Complexes derived from platinum, their preparation and the pharmaceutical compositions which contain them |
| GB9105037D0 (en) * | 1991-03-09 | 1991-04-24 | Johnson Matthey Plc | Improvements in chemical compounds |
-
1998
- 1998-05-27 CZ CZ19981627A patent/CZ288406B6/cs not_active IP Right Cessation
-
1999
- 1999-05-24 CN CN99806647A patent/CN1124278C/zh not_active Expired - Fee Related
- 1999-05-24 JP JP2000550854A patent/JP3647748B2/ja not_active Expired - Fee Related
- 1999-05-24 RS YUP-720/00A patent/RS49739B/sr unknown
- 1999-05-24 UA UA2000116683A patent/UA56314C2/uk unknown
- 1999-05-24 US US09/700,513 patent/US6350737B1/en not_active Expired - Fee Related
- 1999-05-24 DE DE69905714T patent/DE69905714T2/de not_active Expired - Lifetime
- 1999-05-24 CA CA002331464A patent/CA2331464C/en not_active Expired - Fee Related
- 1999-05-24 RU RU2000128647/04A patent/RU2203901C2/ru not_active IP Right Cessation
- 1999-05-24 EP EP99920540A patent/EP1082329B1/en not_active Expired - Lifetime
- 1999-05-24 HU HU0201762A patent/HU228940B1/hu not_active IP Right Cessation
- 1999-05-24 ES ES99920540T patent/ES2194457T3/es not_active Expired - Lifetime
- 1999-05-24 BR BR9910668-0A patent/BR9910668A/pt not_active Application Discontinuation
- 1999-05-24 IL IL13952899A patent/IL139528A/en not_active IP Right Cessation
- 1999-05-24 SK SK1774-2000A patent/SK284398B6/sk not_active IP Right Cessation
- 1999-05-24 AU AU38092/99A patent/AU741381B2/en not_active Ceased
- 1999-05-24 WO PCT/CZ1999/000014 patent/WO1999061450A1/en active IP Right Grant
- 1999-05-24 PL PL344345A patent/PL191131B1/pl not_active IP Right Cessation
-
2000
- 2000-11-17 HR HR20000792A patent/HRP20000792B1/xx not_active IP Right Cessation
- 2000-11-21 BG BG104971A patent/BG64598B1/bg unknown
- 2000-11-23 NO NO20005919A patent/NO328940B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ciampolini et al. | Dinickel and dicopper complexes with N, N-linked bis (cyclam) ligands. An ideal system for the investigation of electrostatic effects on the redox behavior of pairs of metal ions | |
| AU2006234257B2 (en) | Crystals of morphinan derivative and process for producing the same | |
| Serroni et al. | New procedures for the synthesis of mixed-metal and/or mixed-ligand ruthenium (II) and osmium (II) polypyridine supramolecules and the use of these procedures in the preparation of hexanuclear species | |
| IL139528A (en) | Platinum bracelets, processes for their preparation and pharmaceutical preparations containing them | |
| Black et al. | Ligand design and synthesis. III. Cyclic multidentate ligands with 12-and 18-membered rings | |
| Bonati et al. | Bis (alkylamino) carbene complexes of gold (I) and related compounds | |
| CN110449183B (zh) | 离子型铁（iii）配合物在制备烯丙基胺类化合物中的应用 | |
| NZ237443A (en) | Phenalkylethylenediamine and aminomethyltetra hydroisoquinoline derivatives, platinum (ii) and (iv) complexes, methods of preparation and pharmaceutical compositions | |
| EP2134733B1 (de) | Palladium(0)-dibenzylidenaceton-komplexe | |
| CA2712408C (en) | Platinum complex compound and utilization of the same | |
| Boixassa et al. | Synthesis and characterisation of pyrazolic palladium compounds containing alcohol functionality:: rotation around the Pd–N bond | |
| US6589903B2 (en) | Method of synthesizing complexes of platinum and alkenylpolysiloxane, especially of platinum and divinyltetramethyldisiloxane | |
| JP3750011B2 (ja) | 金属錯体の製造方法とアミノ酸修飾金属錯体 | |
| KR101006737B1 (ko) | 구리 촉매를 이용한 2-술포닐이미노인돌린 제조방법 | |
| CN111499607B (zh) | 一种六元芳基内酯或六元芳基内酰胺化合物的制备方法 | |
| CN111689912A (zh) | 3,4-二氢-2(1h)-喹喔啉酮类化合物及制备方法 | |
| CH622544A5 (ja) | ||
| CN117658936A (zh) | 一种3,5,6-三氯-[1,2,4]-噻嗪的合成方法 | |
| MXPA00011624A (es) | Complejo de platino, su preparacion y su aplicacion terapeutica | |
| CN109867633A (zh) | 一种由β-溴苯乙烯合成1,2,3-三氮唑的方法 | |
| JPH0689011B2 (ja) | 新規抗がん性白金錯化合物及びその製造方法 | |
| JPS6344591A (ja) | 白金グリ−ン錯体の製造法 | |
| JPH0349916B2 (ja) | ||
| JPS61148187A (ja) | 新規白金錯体 | |
| JPS61100545A (ja) | ２−アシル−２，５−ジヒドロキシ−１，２，３，４−テトラヒドロナフタセン−６，１１−ジオン誘導体の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |